HINGHAM, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, announced that Harel Gadot, CEO, President and Chairman, will be a featured panelist at The Surgical Disruptive Technology Summit, which is part of SAGES NBT Innovation Weekend, taking place February 19-21 in Houston, TX. SAGES’s mission is to innovate, educate and collaborate to improve patient care, and the SAGES NBT Innovation Weekend se ...

Core Insights - Microbot Medical Inc. is progressing towards a Full Market Release (FMR) of its LIBERTY® Endovascular Robotic System in Q2 2026, building on positive customer feedback and market enthusiasm [1] - The company achieved significant milestones in 2025, including FDA 510(k) clearance and the initiation of a limited market release [1][4] - The target market for LIBERTY includes approximately 2.5 million peripheral endovascular procedures annually in the U.S. [1] 2025 Operational and Business Achievements - Received FDA clearance for the LIBERTY system, the first single-use, remotely operated robotic system for peripheral endovascular procedures [4] - Launched a Limited Market Release, with Emory University Hospital being the first to adopt the system [4] - Established a commercial leadership team and expanded cross-functional teams to support launch readiness [4] - Presented pivotal trial data showing 100% robotic navigation success and a 92% reduction in radiation exposure [4] - Expanded the intellectual property portfolio with 20 patents granted and 52 applications pending [4] Anticipated 2026 Operational and Commercial Milestones - Full Market Release of the LIBERTY System is set for Q2 2026, coinciding with the Society of Interventional Radiology conference [3][4] - Plans to grow the customer base by attracting early adopters and securing new hospitals for medium-to-high volume procedures [3] - Aims to validate the LIBERTY System's market opportunity by expanding the types of procedures and end-user call points [3] - Establish commercial infrastructure for expansion into international markets [3] - Maintain a strong presence at key medical societies and conferences throughout 2026 [5]

Core Insights - Microbot Medical Inc. has announced the commercial availability of its LIBERTY® Endovascular Robotic System in the U.S. following FDA clearance, marking a significant milestone in the introduction of single-use robotic systems for peripheral endovascular procedures [1][2] - The Limited Market Release (LMR) will focus on high procedure volume regions to gather real-world insights and prepare for a Full Market Release (FMR) expected at the Society of Interventional Radiology meeting in April 2026 [1][2] Company Developments - The company has established a core commercial team and secured a third-party logistics partner to support the LMR of LIBERTY® [2] - Positive feedback from physicians and hospital administrators has validated the decision to proceed with the limited market release [1][2] Product Overview - LIBERTY® is the first FDA cleared single-use, remotely operated robotic system designed for precision, efficiency, and safety in endovascular procedures [3] - The product is backed by a strong intellectual property portfolio and a commitment to innovation, positioning Microbot Medical as a leader in the endovascular care market [3]

Core Insights - Microbot Medical Inc. has received its first patent in Japan for the LIBERTY® Endovascular Robotic System, enhancing its intellectual property portfolio [1] - The U.S. FDA granted marketing clearance for the LIBERTY® System on September 8, 2025, prompting the company to accelerate its commercial launch plans targeting 2.5 million peripheral endovascular procedures annually in the U.S. [2] - The company is focusing on the U.S. market while exploring opportunities in other global markets, particularly Japan, which may expedite local approval and adoption of its technology [3] Company Overview - Microbot Medical Inc. is a medical device company specializing in advanced robotic technology aimed at transforming endovascular procedures [3] - The LIBERTY® Endovascular Robotic System is the first single-use, remotely operated robotic solution designed for precision, efficiency, and provider safety [3] - The company is committed to innovation and has a strong intellectual property portfolio to support its growth [3]

Core Insights - Microbot Medical Inc. has received FDA 510(k) clearance for its LIBERTY® Endovascular Robotic System, marking a significant milestone for the company in the commercialization of this innovative medical device [2][3] - The CEO, Harel Gadot, will discuss the implications of this FDA clearance and the company's commercialization plans during a live interview on Benzinga All Access [1] Company Overview - Microbot Medical Inc. is focused on transforming endovascular procedures through advanced robotic technology, with the LIBERTY® Endovascular Robotic System being the first single-use, remotely operated robotic solution designed for precision and efficiency [3] - The company is backed by a strong intellectual property portfolio and is committed to innovation in the field of endovascular care [3]

Core Viewpoint - Microbot Medical Inc. has entered into definitive agreements to exercise preferred investment options, allowing the purchase of up to 13,989,115 shares of common stock, with the offering expected to close in two tranches [1][2]. Group 1: Offering Details - The first closing of the offering is anticipated on or about September 16, 2025, involving the exercise of options for 12,064,627 shares at prices between $1.50 and $2.13 per share [2]. - The second closing is expected by October 15, 2025, for 1,924,488 shares at an exercise price of $2.10 per share [2]. - New unregistered short-term series J preferred investment options will be issued in connection with the cash exercise of these options, with an exercise price of $4.50 per share [2]. Group 2: Financial Proceeds - Gross proceeds from the first closing are projected to be approximately $25.2 million, while the second closing is expected to yield around $4 million [4]. - If fully exercised, the new short-term series J preferred investment options could generate additional gross proceeds of approximately $63 million [4]. Group 3: Use of Proceeds - The net proceeds from the offering will be utilized for the development, commercialization, and regulatory activities of the LIBERTY® Robotic System, potential acquisitions, and general corporate purposes [4]. Group 4: Company Overview - Microbot Medical Inc. is focused on transforming endovascular procedures through advanced robotic technology, with its LIBERTY® Endovascular Robotic System being a key product [8].

Core Insights - Microbot Medical Inc. has received a non-dilutive grant of NIS 2.15 Million (approximately $630,000) from the Israel Innovation Authority to enhance its manufacturing capabilities for the LIBERTY® Endovascular Robotic System, pending FDA marketing clearance [1][2][3] Group 1: Company Developments - The grant is expected to strengthen the company's balance sheet and operational readiness as it awaits FDA's decision on marketing clearance [3] - The Israel Innovation Authority recognized the company's recent achievements, the target market's size, the competitive advantages of a single-use robot, and the expected benefits to healthcare systems [2] - The LIBERTY® System is an investigational device currently pending FDA 510(k) clearance and is not available for sale in the U.S. [3][4] Group 2: Market Positioning - Microbot Medical aims to redefine endovascular robotics and improve care quality for patients globally with its single-use, fully disposable robotic system [4] - The company believes the grant validates its technology and reflects the IIA's confidence in its ability to scale manufacturing and meet business objectives [2][3]

Core Insights - Microbot Medical Inc. is expanding its commercial team in anticipation of the U.S. launch of the LIBERTY Endovascular Robotic System, projected for the third quarter of 2025 [1][2] - The company is actively engaged with the FDA, expecting a 510(k) decision during the third quarter of this year, which aligns with the FDA's original review timeline [1][4] - The addition of Michael Lytle as the head of Sales Operations & Analytics is aimed at enhancing sales infrastructure and optimizing the sales cycle [2][3] Company Developments - The LIBERTY System is currently under FDA review and is not available for sale in the U.S. until clearance is granted [4] - Michael Lytle's previous experience at ZOLL Cardiac Management Solutions is expected to contribute to the company's market targeting and resource allocation [3] - The company aims to redefine endovascular robotics and improve patient care through its innovative, single-use, fully disposable robotic system [5]

Core Insights - Microbot Medical Inc. has strengthened its U.S. commercial leadership team with the addition of a new Vice President of Marketing and a Director of Human Resources, preparing for the launch of its LIBERTY® Endovascular Robotic System [1][4][6] - Positive data from a pivotal study has increased confidence in the market reception of LIBERTY® [1] Leadership Additions - Allison Rosefort has been appointed as Vice President of Marketing, bringing over 15 years of experience in healthcare marketing and a proven track record of driving double-digit revenue growth [2][3] - Lisa Dobbins has joined as Director of Human Resources, with a background in building high-performing teams in the MedTech sector [4][5] Commercialization Strategy - The company aims to be ready for the immediate launch of LIBERTY® following FDA clearance, reflecting its commitment to establishing a robust commercial infrastructure [6] - The recent hiring of Paul Mullen as Vice President of Sales complements the new marketing and HR leadership, enhancing the company's commercialization readiness [1][6] Product Overview - LIBERTY® is an investigational device pending FDA 510(k) clearance and is not currently available for sale in the U.S. [6] - The device is designed to redefine endovascular robotics and improve patient care globally [7]

Market Overview - The wearable robotic exoskeleton market is projected to grow significantly, driven by advancements in robotics, rehabilitation technologies, and workplace safety [1] - The market is expected to reach USD 30.56 billion by 2032, with a CAGR of 43.1% during the forecast period [1] - North America held a market share of 38.64% in 2024, indicating strong regional dominance [1] Technological Innovations - Key trends include the integration of AI and advanced sensor technologies to enhance precision and user experience [2] - AI-powered exoskeletons can adapt to user movements, providing personalized assistance and improving rehabilitation outcomes [2] - Advanced sensors enable intuitive control, making the technology more accessible and effective across various sectors [2] Company Developments - KULR Technology Group, Inc. has partnered with German Bionic to expand into the robotics market, focusing on AI-powered exoskeletons for the U.S. workforce [3][4] - KULR has established a dedicated business unit, KULR AI & Robotics, to drive innovation in robotic solutions [3] - The partnership aims to enhance battery performance and thermal management for high-performance robotics applications [4] Product Impact - The sixth-generation Apogee ULTRA exoskeleton is designed for large-scale deployment, significantly enhancing human energy output and reducing workplace injuries [5] - This technology has shown success in various sectors, including logistics, manufacturing, and healthcare, driving returns on investment and employee satisfaction [5] Other Market Activities - C.H. Robinson Worldwide, Inc. is set to release its Q1 2025 results, indicating ongoing activity in the logistics sector [6] - Pitney Bowes has been recognized as the Top Company in Shipping Software for 2025, highlighting its commitment to innovation in logistics technology [8][9] - GXO Logistics, Inc. has formed a strategic partnership with Hisense to manage logistics operations, showcasing growth in logistics management [9][10]